drugset / Trial / NCT02392507
A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to determine if nab-paclitaxel and carboplatin chemotherapy plus necitumumab is effective and safe in participants with stage IV squamous non-small cell lung cancer.
Timeline
- Start
- 2015-10-12
- Primary completion
- 2018-01-29
- Completion
- 2019-11-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 6 unknown | Intravenous |
| Subject | Necitumumab | Monoclonal antibody | 800 mg | Intravenous |
| Subject | Paclitaxel | Small molecule | 100 mg/m2 | Intravenous |